Topics
High-grade gliomas | Treatment | Targeted therapy | Nivolumab
Home > Publications > Topics > High-grade gliomas > Treatment > Targeted therapy > Nivolumab
Duerinck J, Lescrauwaet L, Dirven
I, Del'haye J, Stevens L, Geeraerts X, Vaeyens
F, Geens W, Brock S, Vanbinst AM, Everaert H, Caljon B, Bruneau M,
Lebrun L, Salmon I, Kockx M,
Tuyaerts S, Neyns B.
Intracranial
administration of anti-PD-1
and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies
in patients
with recurrent high-grade glioma.
Neuro
Oncol. 2024 Oct
16:noae177. doi:
10.1093/neuonc/noae177. PMID:
39406392. Interventional
study. ˍ
Kesari S, Wojcinski A, Pabla S, Seager RJ, Gill JM, Carrillo JA,
Wagle N, Park DJ, Nguyen M, Truong J, Takasumi Y, Chaiken L, Chang
SC, Barkhoudarian G, Kelly DF, Juarez TM.
Pre-radiation
Nivolumab plus ipilimumab in patients with newly diagnosed
high-grade gliomas.
Oncoimmunology.
2024 Nov 21;13(1):2432728. doi:
10.1080/2162402X.2024.2432728. PMID:
39572979. Interventional study. ˍ
Henriksen OM, Maarup S, Hasselbalch B, Poulsen HS, Christensen IJ,
Madsen K, Larsen VA, Lassen U, Law I.
Magnetic
resonance imaging and
o-(2-[18F]fluoroethyl)-l-tyrosine
positron emission tomography for
early response assessment of
nivolumab and bevacizumab in patients with
recurrent high-grade astrocytic
glioma.
Neurooncol
Adv. 2024 Oct 24;6(1):vdae178. doi:
10.1093/noajnl/vdae178. PMID:
39659835. Interventional study. ˍ